Vitamin D Receptor Activation Protects Against Lipopolysaccharide-Induced Acute Kidney Injury Through Suppression Of Tubular Cell Apoptosis
Jie Du,Siqing Jiang,Zhaoxin Hu,Shiqi Tang,Yue Sun,Jinrong He,Zhi Li,Bin Yi,Jianwen Wang,Hao Zhang,Yan Chun Li
DOI: https://doi.org/10.1152/ajprenal.00332.2018
2019-01-01
American Journal of Physiology - Renal Physiology
Abstract:Acute kidney injury (AKI) is a common complication of sepsis characterized by a rapid degradation of renal function. The effect of vitamin D on AKI remains poorly understood. Here, we showed that vitamin D receptor (VDR) activation protects against lipopolysaccharide (LPS)-induced AKI by blocking renal tubular epithelial cell apoptosis. Mice lacking VDR developed more severe AKI than wild-type (WT) control mice after LPS treatment, which was manifested by marked increases in body weight loss and accumulation of serum blood urea nitrogen and creatinine as well as the magnitude of apoptosis of tubular epithelial cells. In the renal cortex, LPS treatment led to more dramatic downregulation of Bcl-2, more robust induction of p53-upregulated modulator of apoptosis (PUMA) and miR-155, and more severe caspase-3 activation in VDR knockout mice compared with WT control mice. Conversely, paricalcitol pre-treatment markedly prevented LPS-induced AKI. Paricalcitol ameliorated body weight loss, attenuated serum blood urea nitrogen and creatinine accumulation, blocked tubular cell apoptosis, prevented the suppression of BCl-2, and reversed PUMA and miR-155 induction and caspase-3 activation in LPS-treated WT mice. In HK2 cells, LPS induced PUMA and miR-155 by activating NF-kappa B, whereas 1,25(OH)(2)D-3 blocked PUMA and miR-155 induction by repressing NF-kappa B activation. Both PUMA and miR-155 target Bcl-2 to promote apoptosis; namely. PUMA inhibits Bcl-2 activity, whereas miR-155 promotes Bcl-2 mRNA degradation and inhibits Bcl-2 protein translation. Collectively, these data provide strong evidence that LPS induces tubular cell apoptosis via upregulating PUMA and miR-155, whereas vitamin D/VDR signaling protects against AKI by blocking NF-kappa B-mediated PUMA and miR-155 upregulation.